BioMarin announces BMN-111 program for treatment of achondroplasia

Links shared publicly online about this topic.

790
total visits

BioMarin announces BMN-111 program for treatment of achondroplasia

BioMarin Pharmaceutical Inc. today announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter of 2011 and to initiate a Phase 1 clinical trial by the first quarter of 2012.

View full resource at news-medical.net

Tags: Pharma, Phase 1 Clinical Trial, Clinical Trial

Most Recently Shared on October 19, 2010 at 3:16 pm By:

News-Medical.Net

Obesity News: BioMarin announces BMN-111 program for treatment of achondroplasia: BioMarin Pharmaceutical Inc. t... http://twurl.nl/u4afxn

2 years ago...

Retweet

Favorite

Also Shared By:

News-Medical.Net

BioMarin Announces Program For BMN-111 For The Treatment Of Achondroplasia

medicalnewstoday.com — “BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter of 20” View full resource at medicalnewstoday.com